

emea CONFERENCE



TOPRA – The Organisation for Professionals in Regulatory Affairs

Reference: CA7/08



Medicines Legislation

Aims of the course

This conference follows on from the success of two earlier joint meetings between TOPRA and the EMEA and its aim is to provide a practical insight into the workings of the EMEA. The aim is to bring together regulatory personnel from both the national agencies and industry in order to share regulatory knowledge, specifically when coordinated via the EMEA.

You will hear not only about the existing processes such as the centralized procedure and scientific advice but also how the new paediatric committee has performed over its first year; the impact of the new rules on pharmacovigilance, how the Advanced Therapy committee will be organized and Transparency – how open are we with each other?

The last session of the conference will provide an open forum for discussing emerging topics. An aim of this meeting is also to facilitate networking and there will be ample opportunity to meet many regulatory personnel from agencies and industry and particularly from the EMEA during the refreshment break, lunches and at the evening drinks reception.

Who should attend

This conference will cover all the major areas of medicines legislation covered by the European Medicines Agency. If you are working at a Europe wide level then this meeting is a must for all levels of regulatory personnel. It will provide you with practical advice on the working of the EMEA within the European regulatory network. As well as speakers from the EMEA there will also be representatives of the national agencies and the European Commission plus Industry representatives to offer their experiences.

Conference programme includes:

- New Regulatory Legislation
- Scientific Advice
- Paediatrics
- Advanced Therapies
- EMEA processes and procedures
- Pharmacovigilance
- Transparency
- Open Question Session

Two-day Conference

Date:

Tuesday 2nd -
Wednesday 3rd
December 2008

Venue:

Hilton London Canary
Wharf Hotel, London
E14 9SH, UK

Timings:

Registration:
09.00 Tuesday
2nd December 2008
Start of Conference:
09.30 Tuesday
2nd December 2008
Close of Conference:
16.00 Wednesday
3rd December 2008



Lifelong Learning (LLL):

This meeting contributes 12 hours of training to your LLL (sometimes known as Continuing Professional Development) and will enhance your Regulatory Skills relevant in the areas of human and veterinary medicines

For more information or to obtain a booking form, please contact TOPRA via email: meetings@topra.org or tel: +44 (0) 207 538 9502 or go to the website: www.topra.org

email: meetings@topra.org tel: +44 (0) 20 7538 9502 fax: +44 (0) 20 7515 7836 web: www.topra.org



Working party

Peter Bachmann

BfArM, Germany

Liz Gifford

GlaxoSmithKline, UK

Anthony Humphreys

EMA

Brenton E James

Consultant in Strategic

Regulatory Affairs in

Europe, UK

Donna Mountfield

Chugai Pharma Europe

Arielle North

EMA

Beatrice Oberlé-Rolle

Novartis, Switzerland

Giuseppe Pimpinella

AIFA, Italy

Agnes Saint Raymond

EMA

Tomas Salmonson

Vice chair CHMP, EMA

and MPA, Sweden

Supported by TOPRA staff:

Christopher Bailey

Conference and Training

Programme Manager

Erik Smit

Business Development Manager

Medicines Legislation

Speakers include

Daniel Brasseur

chair of Paediatric Committee

(PDCCO), EMA

Axel Breitstadt

MSD (Europe) Inc, Belgium

Melanie Carr

EMA

Patrick Celis

EMA

Ali Harrison

AstraZeneca, UK

Martin Harvey Alchurch

EMA

Ian Hudson

MHRA, UK

Alan Hunter

TOPRA President

David Laurie

Novartis, Switzerland

Patrick LeCourtois

EMA

Marisa Papaluca

EMA

John Purves

EMA

June Raine

chair CHMP Pharmacovigilance

working party and MHRA, UK

Irene Sacristan Sanchez

Unit F2, European Commission

Vincenzo Salvatore

EMA

Christian Schneider

PEI, Germany

Thomas Severin

Novartis, Switzerland

Lisette Tiddens-Engwirda

Vice chair EMA Management

Board, Standing Committee of European

Doctors, Belgium

Noel Wathion

EMA

Anne Wigmore

GlaxoSmithKline, UK

Other speakers from National Competent

Authorities, EMA, European Commission,

Industry and other health care related

bodies have been invited.



**Book
Early**
Places limited



Conference programme includes:

2nd December 2008

New Regulatory Legislation

This session will review the legislation introduced over the past year and that coming up in the near future. The impact upon the EMEA, the European Commission, the EU member states and the committees that they support within the EMEA will be discussed.

Scientific Advice

New developments in the area of Scientific Advice (SA) and informal briefing meetings: faster/competitive SA process/parallel SA process, SA on conditional approval, new process for Qualification Advice e.g. for biomarkers and experiences with biomarker qualification pilots under the umbrella of Innovation Task Force (ITF) briefing meetings.

Paediatrics

This session will review the experience of the implementation of the Paediatric Regulations for investigational products (Article 7) and line extensions for patent protected products (Article 8). Experience will focus on applications for Paediatric Investigational Plans, deferrals and waivers from the EMEA and industry perspective. In addition, an update on paediatric activities from the national agencies perspective (Article 45) will be given.

Advanced Therapies

The Advanced Therapies Regulation (Regulation (EC) No 1394/2007) comes into effect on 30 December 2008 and this session will review the new committee and processes affected by this new regulation

3rd December 2008

EMA processes and procedures

The scope of the centralised procedure has widened over the years since it was first introduced and now many companies are also choosing it as the procedure of choice for products where the centralised procedure is not obligatory – how has the procedure held up over the last year and what is the future? What should be in the centralised procedure versus the Decentralised procedure?

Pharmacovigilance

A number of changes in pharmacovigilance reporting have recently been announced and these will be reviewed in this session

Transparency

Openness is an increasing fact of modern life – what progress has been made and will be made towards increasing transparency?

Open Question Session

This final session will discuss all the latest emerging topics. Delegates are encouraged to submit their questions before the meeting and also questions will be taken from the floor by the panel of regulatory experts.

For more information or to obtain a booking form, please contact TOPRA via email: meetings@topra.org
or tel: +44 (0) 207 538 9502 or go to the website: www.topra.org

email: meetings@topra.org tel: +44 (0) 20 7538 9502 fax: +44 (0) 20 7515 7836 web: www.topra.org



Date: **Tuesday 2nd - Wednesday 3rd, December 2008** Venue: **Hilton London Canary Wharf Hotel** Reference: **CA7/08**

Two-day conference

Ways to book

Please complete in block capital letters and return this form with payment to TOPRA using one of the following methods:

Post: TOPRA, 7 Heron Quays, Marsh Wall, London E14 4JB, UK

Fax: +44 (0) 20 7515 7836

On receipt of your booking form we will confirm your provisional place in writing and provide directions to the venue. An invoice will be sent separately. To ensure admission, payment must be received prior to the meeting.

If you have any queries, contact us on: +44 (0) 20 7538 9502 or meetings@topra.org

Dr ☐ Mr ☐ Mrs ☐ Ms ☐ Other

Family name

First name Male ☐ Female ☐

Company name

VAT reg. no.

Job title

Telephone

Fax

E-mail

Work Address

City Postcode

Country

Invoice Address
(If different from above address)

City Postcode

Country

Special dietary requirements

Experience in the Subject Area

Negligible ☐ Average ☐ Considerable ☐

Your current role

Generics ☐ CRO ☐ European role ☐ Global role ☐ Local affiliate ☐

Other

Experience in Regulatory Affairs Years Months

Please indicate if in your regulatory experience you have worked in one or more of the following areas:

1) CMC ☐ 2) EU clinical trials ☐ 3) Variations ☐ 4) Medical Technologies ☐

Discounted fees

Personnel in full-time education, working in academia (full-time) or working for a regulatory body may be entitled to a discount on the below fees. Please contact the TOPRA office for details.

Fees and Payment method

Members ☐ €1,703.75 = €1,450.00 + €253.75 (17.5% GB VAT)

Non-Members ☐ €2,115.00 = €1,800.00 + €315.00 (17.5% GB VAT)

Cheque enclosed ☐ Cheque No.

Bank transfer ☐ Date of transfer / /

Please charge my debit/credit card ☐ Purchase Order No.

Debit/Credit card details

(For cards accepted, see payment section below)

Debit Card ☐ Visa ☐ MasterCard ☐ American Express ☐

Card No.

Expiry date /

Security code Visa, MasterCard, Debit cards: the last 3 digits AFTER the card number in the signature area of the card.

Card holder name (as given on card)

Billing address for card (must be provided if different from the Work Address)

City Postcode

Country

TOPRA will seek authorisation from the card-issuing company before confirming any reservation (VAT Registration No.: GB 342 7398 40).

SIGNATURE	DATE
-----------	------

Terms and conditions (Please note: new TOPRA bank details)

Payment: may be made in Euro or Sterling by cheque or bank transfer.

Debit/Credit cards will be charged in Sterling.

- Cheques:** must be made payable to TOPRA and drawn on a UK bank.
- Debit/Credit cards:** for payment by card please complete the relevant details above. Cards accepted: AMEX, Debit MasterCard, Delta, Electron, Maestro, MasterCard, Solo, Visa. All cards will be charged in Sterling.
- Bank Transfers:** may be made to Lloyds TSB Bank PLC. Please quote the delegate's name and the course reference in the transmission details. The delegate must pay all bank charges.
 - Sterling Transfers:** Account No: 00340310, Sort Code: 30-00-09, IBAN: GB45 LOYD 3000 0900 3403 10, BIC: LOYDGB21013
 - Euro Transfers:** Account No: 86330987, Sort Code: 30-00-09, IBAN: GB19 LOYD 3000 0986 3309 87, BIC: LOYDGB21013
- Your place is secured only upon receipt of full payment.

Please note: Fee excludes accommodation and travel. The delegate ticket includes refreshments at coffee breaks, buffet lunches and drinks reception. Unless stated otherwise the official language of all our meetings is English. It may be necessary for reasons beyond the control of the organisers to alter the dates, venue, timing and content of the programme (including speakers) without prior notice; TOPRA regrets that it cannot accept liability for losses incurred by delegates in these circumstances. Meals requiring special preparation (such as Kosher) may incur additional costs.

Cancellations: All cancellations must be received in writing 21 calendar days before the start of the course and will be subject to an administration fee of €200. Payment can be in Euro or Sterling. For cancellations after this time, or if the delegate fails to attend the course, no refund of fees will be given. Substitutions may be made at any time. TOPRA reserves the right to cancel the course at any time without liability. In these circumstances, delegates will be offered an alternative date, a credit note or a full refund.

Additional support: Please advise TOPRA, at least one month before the meeting, if you have any disability that may require additional support. TOPRA makes no distinction in its admission policy with regards to disability. TOPRA will make every reasonable effort to supply delegates with services that meet their needs.

Liability: TOPRA regrets that it cannot accept liability for losses incurred by delegates in the event of postponement or other alterations to the meeting, i.e. timing, venue, etc. Normal TOPRA terms and conditions apply; please contact the TOPRA office for further details.

Data protection: TOPRA is registered under the Data Protection Act 1998. Your details will not be passed to other companies. If you would like us to change any details or if you do not wish to be sent marketing communications about our meetings please write to TOPRA e-mail address: membership@topra.org

- ☐ We may occasionally send you promotional or other information about TOPRA's products and services. If you do not wish to receive this information, you can opt out by ticking this box
- ☐ We may occasionally send you promotional or product information from organisations and companies other than TOPRA. If you do not wish to receive this information, you can opt out by ticking this box